Industry news

Scientists use magnetic nanoparticles to place stem cells to treat TBI

Stacy Lawrence / Fierce Medical Devices

Using stem cells to treat traumatic brain injury is thought to be promising, but delivering those cells via an injection into the central nervous system is fraught with risk including intracranial hemorrhage and the simple failure of the cells to reach the correct area of the brain.

30 October 2015

Transcend Medical and Glaukos Corporation Settle Patent Litigation

Transcend Medical, Inc. ("Transcend") announced today that it has reached agreement with Glaukos Corporation ("Glaukos") to settle the patent litigation pending between them in the U.S. District Court for the District of Delaware. Among other things, the settlement provides that in exchange for a perpetual, worldwide covenant by Glaukos not to sue Transcend's CyPass minimally invasive glaucoma surgery (MIGS) technologies on any of Glaukos' patents, Transcend will provide Glaukos with a one percent (1%), dollar- and time-capped payment on Transcend's commercial CyPass sales. 

Why the FDA Is Worried About Chinese Drugs in Your Medicine Cabinet

Bloomberg News

When FDA inspectors showed up at a Chinese company that supplies key ingredients to two of the U.S.’s biggest drug companies, a curious thing happened. After lunch, they walked into a quality control lab on the second floor, where they saw a worker pull what looked like a memory stick from a computer and put it in the pocket of his lab coat. The inspectors asked to see what he’d taken.

Top U.S. drugmakers ride new products to strong results

Bill Berkrot / Reuters

Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc, Merck & Co and Bristol-Myers Squibb Co to stronger-than-expected third-quarter profits. The results, announced on Tuesday, demonstrate that the "patent cliff" that had been hurting earnings as huge-selling drugs like Pfizer's Lipitor and Bristol's Plavix went generic is now well behind these companies.

Drug-device combo from Wyss takes a new approach on treating stroke

John Carroll / FierceBiotechResearch

Scientists at the Wyss Institute have led the development of a new drug-device combo aimed at swiftly dissolving blood clots in the brain that cause stroke. The key to the new approach are biodegradable nanoparticles that are coated with a "clot-busting" drug dubbed tissue plasminogen activator, or tPA, which are designed to mimic the activity of blood platelets. They use a stent to open up a narrow opening in a blocked blood vessel.

29 October 2015

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2015.
 

29 October 2015

Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today the initiation of the clinical phase of its intravenous (IV) ganaxolone program in Status Epilepticus (SE). Data from preclinical studies yielded positive results testing ganaxolone IV in benzodiazepine-resistant SE, which support progressing ganaxolone IV to human clinical trials. Ganaxolone IV promoted survival and showed better or comparable reversal of seizures than the endogenous neurosteroid, allopregnanolone, in clinically translatable rodent models of SE.  The studies were conducted at two separate laboratories using different measurements. 

Epigenetics Market Size to Reach $16.31 Billion By 2022: Grand View Research, Inc.

Grand View Research, Inc.

he global epigenetics market is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.

Europe Hits €9.5B in VC Invested; Overall Private Activity Down 36% Since 1Q 2014

PitchBook Blog

The number of European venture financings has slid steadily since the beginning of 2014. But the total value of VC invested has never been higher. Through the end of 3Q, the total value of VC invested in European startups hit nearly €9.5 billion, eclipsing the total seen in 2014. 

Big Pharma follows cash-strapped seniors onto the darknet

Nick Paul Taylor / Fierce Biotech IT

The existence of an ever-present pool of people who struggle to afford medicines and online bazaars that can meet their needs has brought two new groups to the hidden underbelly of the internet: Big Pharma and cash-strapped seniors